CEBPA and acute myeloid leukemia: Here, we demonstrated that AML patients with a C-terminal CEBPA mutation showed elevated miR-182 expression levels, while both CEBPA wild-type- and CEBPA N-terminal mutated AML patients showed no significant changes compared to bone marrow mononuclear cells from healthy donors (Fig. 3b).